glp 1 south korea tightens oversight as GLP-1 obesity drug misuse rises Rivalry heats up in the

Eden does not produce medications, and Eden is not a medical provider

Least stable: Large peptides and complex proteins with extensive post-translational modifications

Adults (2019-2024) Prescription Patterns and Healthcare Provider Trends Advanced practice practitioners and primary care physicians increasingly prescribe these medications, with APPs' share rising from 25.3% to 40.6% between 2017 and 2024 ^22

Each batch is independently tested by a third-party laboratory not in-house

Han Y, Kwon EY, Yu MK, Lee SJ, Kim HJ, Kim SB, et al

Oral formulations will grow to capture 25% share as bioavailability improves and new small-molecule GLP-1s reach the market, appealing to segments seeking greater convenience or avoiding injection-site issues